Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

“The real goal in the whole Oral Mucositis arena is to try and prevent the development of this...”

R Straube SNGX CMO
(1m 15 secs in)

(bingo... spot on... nothing Hyperbolic in saying that)

“There is one drug available but only those with blood cancers.”

(enter B-OM... less so dusquetide—targeting reduction / delay only symptoms)

Global Bn+ Opportunity for a Preventative OM Drug like Brilacidin — as an Oral Rinse (no IV required) — and no safety issues

More from Straube

Impact of OM on patient

Their Ph1b/2 recap (Reduction)

SNGX
Efficacy / Incidence of SOM
(Secondary endpoint)

Placebo 74% (n=38)
1.5mg 69% (n=36)
3mg 67% (n=3)
6mg 79% (n=19)

So 5pt, 7pt better spread against Pbo, with the 6mg doing worse by 5pt...

B-OM ?

· Incidence of severe OM in Modified Intent to Treat (mITT) Population: Brilacidin 42.9%, Placebo 60.0%. 
· Incidence of severe OM in Per Protocol (PP) Population: Brilacidin 36.8%, Placebo 60.0%.

Overall reduction in observed severe Oral Mucositis (WHO Grade ≥ 3) in the Brilacidin-OM treatment group from that seen in the control group ([incidence control - incidence active]/incidence control) was: 28.5% (mITT population) and 38.7% (PP population).

(seems like ours is much better than theirs... Preventative)
(just need to partner up to giddy up)